DiaMedica Therapeutics Inc.

Good morning, ladies and gentlemen, and welcome to the Diamedic Therapeutics first quarter 2026 earnings conference call. An audio recording of this webcast will be made available shortly after the call today on Diamedic's website at www.diamedic.com in the investor relations section. Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risk and uncertainties. that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results, appear in the sections entitled Cautionary Statement Notes Regarding Forward-Looking Statements in the company's press release issued yesterday under the heading Risk Factors in Diomedica's Most Recent Annual Report on Form 10-K and Most Recent Quarterly Report on Form 10-Q. Diomedica's SEC filings are available at www.sec.gov on its website. Please note that any comments made on today's call speak only as of today, May 7th, 2026, and may no longer be accurate at the time of any replay or transcript rereading. Please follow management's remarks. We will open the phone lines for questions. I would now like to introduce your host for today's call, Rick Pauls. Diomedica's President and Chief Executive Officer.

Mr. Paul, you may begin. Thank you, operator, and thank you all for joining us today.

With me this morning are Dr. Julie Krupp, our chief medical officer, and Scott Kallen, our chief financial officer. Given that our last call was only five weeks ago, we'll try to keep our remarks short. We are pleased with the progress we've made so far in 2026 as we continue to advance DM-109 across both our preeclampsia and acute ischemic stroke programs. Most importantly for our shareholders, we're poised to deliver multiple clinical milestones between now and the end of 2027, all of which could provide significant validation of the value of DM-199. We will also weigh the risks and advantages of providing interim updates as clinically meaningful data emerges ahead of formal readouts. We're particularly interested in completing the interim analysis for our stroke program. We've been working diligently on the Remedy 2 stroke trial for a long time, battling through some significant challenges emanating from the COVID pandemic. With enrollments having surpassed 70%, we expect that the interim analysis will validate all of the hard work that has gone into the program. I now turn the call over to Julie to provide additional detail on her preeclampsia and stroke programs.